美国免疫功能低下成人中的带状疱疹疫苗接种
该回顾性队列分析利用IQVIA理赔数据评估≥19岁免疫功能低下者对重组带状疱疹疫苗(RZV)的接种率和完成率。截至2023年6月,接种率为8.2%,启动接种者6个月和12个月完成率分别为62.1%和70.0%,完成第二剂的中位时间为4.2个月。结论认为ACIP推荐后20个月内接种率低,但一旦启动则能及时完成。
要点
- 截至2023年6月,2,595,572名RZV初治免疫功能低下患者中接种率为8.2%。
- 启动接种者6个月和12个月完成率分别为62.1%和70.0%,第二剂中位时间4.2个月。
- 调整后,HIV、西班牙裔、非西班牙裔亚裔/其他种族及较高教育/收入与接种 odds 升高相关。
核心结论
- ACIP推荐后20个月内,免疫功能低下患者的RZV接种率低,但一旦启动接种则可能及时完成。
- 需要有针对性的努力来改善带状疱疹预防,尤其是在较年轻的免疫功能低下人群中。
研究设计与样本
- 回顾性队列分析,使用IQVIA理赔数据评估RZV初治的≥19岁免疫功能低下患者。
- 免疫功能低下状态基于ACIP投票日期前6个月内的自身免疫/免疫抑制疾病和/或抗肿瘤/免疫抑制药物使用。
- 接种率评估截至2023年6月;6个月和12个月完成率在2023年1月前接种第一剂的患者中评估。
- 采用Kaplan-Meier分析估计完成时间,广义估计方程模型评估与接种和1-6个月内完成相关的因素。
主要发现
- 共纳入2,595,572名RZV初治患者,其中75.7%年龄≥50岁。
- 截至2023年6月,总体接种率为8.2%,19-49岁为2.0%,≥50岁为10.1%。
- 在RZV启动者中,6个月和12个月内完成第二剂的比例分别为62.1%和70.0%,第二剂中位时间为4.2个月。
- 在任意时间完成两剂的患者中,88.5%在1-6个月内接种第二剂。
- 调整后,接种 odds 升高的因素包括HIV、西班牙裔、非西班牙裔亚裔/其他种族、较高教育/收入;降低的因素包括较年轻年龄、较大社会劣势、移植、癌症或抗肿瘤/免疫抑制药物。
关键数值与推荐
- 2021年10月,ACIP推荐≥19岁免疫功能低下成人接种两剂RZV,间隔1-6个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In October 2021, the Advisory Committee on Immunization Practices (ACIP) recommended two doses of recombinant zoster vaccine (RZV) 1-6 months apart for immunocompromised adults aged ≥19 years, though usage data remain limited. METHODS: This retrospective cohort analysis used IQVIA claims data to evaluate RZV uptake (one or more doses) and completion (two doses) among RZV-naïve immunocompromised patients aged ≥19 years. Immunocompromised status was based on autoimmune/immunocompromising conditions and/or antineoplastic/immunocompromising medication use, during the 6 months before the ACIP voting date. Uptake was assessed through June 2023. Six- and 12-month completion was assessed in patients with a first dose before January 2023. Time to completion was estimated by Kaplan-Meier analysis. Generalized estimation equation models assessed factors associated with uptake and completion within 1-6 months. RESULTS: Among 2,595,572 RZV-naïve patients (75.7 % aged ≥50 years), uptake was 8.2 % (2.0 % for age 19-49 years; 10.1 % for ≥50 years) by June 2023. Among RZV initiators, 62.1 % and 70.0 % received a second dose within 6 and 12 months, respectively. Median time to second dose was 4.2 months. Among patients with two doses (any time), 88.5 % received the second dose within 1-6 months. After adjustment, factors indicating higher odds of uptake included HIV, Hispanic ethnicity, non-Hispanic Asian/other race, and higher education/income, lower odds included younger age, greater social disadvantage, transplant, and cancer or antineoplastic/immunocompromising medication. Factors associated with increased odds of series completion included higher income and first-dose administration in a pharmacy, while factors with reduced odds included younger age, non-Hispanic African American or Hispanic race/ethnicity, Charlson Comorbidity Index score ≥ 2, and transplant. CONCLUSIONS: RZV uptake among immunocompromised patients was low in the 20 months following the ACIP recommendation. However, once initiated, timely completion was likely. Targeted efforts are needed to improve HZ prevention, especially in younger immunocompromised populations.
引用
- Carrico J, McGuiness C, Yasuda M, et al. Herpes zoster vaccination among immunocompromised adults in the United States. Vaccine. 2025. PMID: 41406649. doi:10.1016/j.vaccine.2025.128124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。